請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41024
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江文章 | |
dc.contributor.author | Hsing-Hua Hsu | en |
dc.contributor.author | 許倖華 | zh_TW |
dc.date.accessioned | 2021-06-14T17:12:28Z | - |
dc.date.available | 2011-08-06 | |
dc.date.copyright | 2008-08-06 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-25 | |
dc.identifier.citation | 中山宗春。1960。薏苡仁抗癌作用之研究。日本外科學會誌 61:234。(日文)
中山恆明。1959。漢方藥療法之經驗。日本醫師會雜誌 41:(12).945-950。(日文) 王思涓。2002。薏苡籽實中特殊生理機能性成分的定量分析與比較。國立臺灣大學食品科技研究所碩士論文。臺北。 王德宏教授消化醫學基金會。2000。腸治久安-淺談大腸直腸疾病。健康文化事業股份有限公司。p.158-168。 何菁菁。2000。糙薏苡對STZ所誘發之糖尿病大白鼠脂質與醣類代謝的影響。國立臺灣海洋大學食品科學研究所碩士論文。基隆。 吳宜娟。2001。薏仁加工產品對高血脂質大鼠代謝之影響。國立臺灣大學食品科技研究所碩士論文。臺北。 李明怡。2008。薏仁麩皮中防癌即抗發炎活性成分之分離與鑑定。國立臺灣大學食品科技研究所博士論文初稿。臺北。 李鳳云,陳浩然,馮曉東,柳世英,姜力。1994。中藥薏苡仁抗腫瘤作用的研究。實用腫瘤學雜誌3 : 59。 杜姿瑩。1999。糙薏仁降血脂作用之研究。國立臺灣大學食品科技研究所碩士論文。臺北。 林紓慧。2007。薏苡麩皮乙醇萃取物及乙醇萃取殘餘物對F344鼠大腸癌前期病變預防效果之探討。臺北醫學大學保健營養學系碩士論文。臺北。 施宛宜。2001。以細胞模式探討薏苡籽實萃取物對COX-2和iNOS之表現量的影響。國立臺灣大學食品科技研究所碩士論文。臺北。 施純光。2004。薏仁對大腸癌形成之影響。國立臺灣大學食品科技研究所博士論文。臺北。 夏詩閔。2001。薏苡籽實萃取物對於大鼠卵巢性類固醇激素以及腦下腺黃體促進素和濾泡刺激素分泌之效應。國立臺灣大學食品科技研究所碩士論文。臺北。 徐明麗。1997。薏仁抗過敏與抗腫瘤之研究。國立臺灣大學食品科技研究所碩士論文。臺北。 徐欣億。2003。糙薏仁對特異性免疫反應及呼吸道發炎影響之研究。國立臺灣大學食品科技研究所博士論文。臺北。 高德錚、梁純玲。1986。省產薏苡品質之檢定。臺中農業改銀場研究彙報13: 11-18。 梁金銅。2002。臺大外科住院醫師醫療手冊。金名圖書有限公司。p.234-242。 郭靜娟。2001。薏苡籽實之抗氧化成分及其抑制自由基傷害之研究。國立臺灣大學食品科技研究所博士論文。臺北。 陳維熊,魏承生。2004。中西醫會診-大腸癌。書泉出版社。p.21。 黃士禮,陳瑤峰與江文章。1994。省產薏苡籽實中氨基酸、脂肪酸和一般組成分分析。食品科學 21: 67-74。 黃士禮,江文章。1999。薏苡籽實各部位之組成及其丙酮萃取液之抗突變作用。食品科學26:121-130。 黃士禮。1996。薏苡籽實貯藏條件、抗突變效應及抗腫瘤效應之研究。國立臺灣大學食品科技研究所博士論文。臺北。 黃宗人。2000。認識大腸癌-病人想知道的基本知識。長年出版社。p.22-23。 黃博偉。2003。不同糙薏仁成分對糖尿病大白鼠醣代謝級脂質代謝的影響。國立臺灣大學食品科技研究所博士論文。臺北。 劉桂萍。2000。薏苡殼甲醇萃取物清除自由基成分之分離與純化。國立臺灣大學食品科技研究所碩士論文。臺北。 蔡至宏。1997。薏苡種皮水溶性物質之抗致突變性及其分離與純化。國立臺灣大學食品科技研究所碩士論文。臺北。 謝銘鈞。2004。臺大內科學講義。橘井文化事業股份有限公司。p.617-624。 簡雅琳。1998。薏苡殼油溶性萃取物的抗突變性成分之分離與純化。國立臺灣大學食品科技研究所碩士論文。臺北。 蘇珮琪。1996。薏苡對高脂症和糖尿症病患血漿脂質和血糖的影響。輔仁大學食品營養研究所碩士論文。臺北。 Aarnio M, Mustonen H, Mecklin JP and Jarvinen HJ. 1998. Prognosis of colorectal cancer varies in different high risk conditions. Ann Med 30:75-80. American Institute of Nutrition 1977. Report of American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 107:1340-1348. American Institute of Nutrition 1980. Second report of the ad hoc committee on standards for nutritional studies. J Nutr 110:1726. Aoki M, Tuzihara N. 1984. Effects of the hatomugi (Coix lachryma-jobi L. var. ma-yuen) on the blood pressure, cholesterol absorption and serum lipids level. Kaseigaku Zasshi 35: 89-96. Aoki M, Tuzihara N. 1985. Effects of the hatomugi (Coix lachryma-jobi L. var. ma-yuen) on the hyperlipidemia in rats. Kaseigaku Zasshi 36: 27-33. Bird RP. 1987. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37:147-151. Bird RP. 1995. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55-71. Bird RP. 1998. Aberrant crypt foci system to study cancer preventive agents in the colon. In Methods in Molecular Medicine, Vol.14, M. Hanausek and Z. Walaszek (Ed), p465-474, Humana Press Inc., Totowa, NJ. Bird RP and Good CK. 2000. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112-113:395-402. Caderni G, Giannini A, Lancioni L, Luceri C, Biggeri A and Dolara P. 1995. Characterization of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis. Brit J Cancer 71:763-769. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M and Dolara P. 2003. Idetification of mucin-fepleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 63:2388-2392. Cassand IL, Hardman WE and Heitman DW. 1997. The nonfermentable dietary fiber lignin alters putative colon cancer risk factors but does not protect against DMH-induced colon cancer in rats. Cancer Res 28:170-176. Chang HC, Huang YC and Hung WC. 2003. Antiproliferative and chemopreventive effects of adlay seed on lung cancer in vitro and in vivo. J Agric Food Chem 51: 3656-3660. Chen T, Hwang H, Rose ME, Nines RG and Stoner GD. 2006. Chemopreventive properties of black raspberries in n-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res 66: 2853-2859. Cianchi F, Cortesini C and Bechi O. 2001. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121:1339-1347. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Felice DA, Perigli G, Mazzanti R and Masini E. 2004. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10:2694-2704. Davies MJ, Bowey EA, Adlercreutz H, Rowland IR and Rumsby PC. 1999. Effect of soy or rye supplementation of high-fat diets on colon tumour development in azoxymethane-treated rats. Carcinogenesis 20:927-931. De Filippo C, Caderni G Bazzicalupo M, Briani C, Giannini A, Fazi M and Dolara P. 1998. Mutations of the APC gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats. Br J Cancer 77 :2148-2151. De Flora S, Bennicelli C and Bagnasco M. 1999. Rationale and mechanism of cancer chemoprevention. In Chemoprevention of Cancer: A Clinical Update, H.-J. Seen, A, Costa, and V.C. Jordan (Ed), p.29-44, Spring-Verlag Berlin, Heidelberg, Berlin. Dimberg J, Samuelsson A, Hugander A and Soderkvist P. 1999. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 45:730-732. Deschner EE. 1974. Experimentally induced cancer of the colon. Cancer 34:824-828. Dolara P, Caderni G and Luceri C. 2000. Surrogate endpoint biomarkers for human colon carcinogenesis. Toxicol Lett 112-113:415-420. Duke JA. 1992. Handbook of phytochemical constituents of GRAS herbs and other economic plants. CRC Press. Boca Raton. Florida. Ekbom A, Helmnick C, Zaelf M and Adami HO. 1990. Ulcerative colitis and colorectal cancer. A population based study. New Engl J Mod 323:1228-1233. Exon JH, South EH, Magnuson BA and Hendrix K. 2001. Effect of indole-3-carbinol on immune responses, aberrant crypt foci and colonic crypt cell proliferation in rats. J Toxicol Environ Health Part A 62:561-573. Farrow DC, Vaughan TL, Hanscln PD, Stanford JL, Rische HA and Gammon MD. 1998. Use of aspirin and other nonsteroial-anti-inflammatiory drugs and risk of esophageal and gastic cancer. Cancer Epidemiol Biomarkers Prev 7:97-102. Fearnhead NS, Britton MP, Bodmer WF. 2001. The ABC of APC. Hum Mol Genet 10:721-733. Femia AP, Dolara P and Caderni G. 2004. Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are usful biomarkers for colon carcinogenesis. Carcinogenesis 25:277-281. Femia AP, Bendinelli B, Giannini A, Salvadori M, Pinzani P, Dolara P and Caderni G. 2005. Mucin-depleted foci have β-catenin gene mutations, altered expression of its protein, and are time-dependent in the colon of 1,2-dimethylhydrazine-treated rats. Int J Cancer 116:9-15. Femia AP, Dolara P, Giannini A, Salvadori M, Biggeri A and Caderni G. 2007. Frequent mutation of APC gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res 67: 445-449. Fiala ES. 1975. Investigation into the metabolism and mode of action of the colon carcinogen 1,2-dimethylhydrazine. Cancer 36:2407-2412. Fiala ES, Joseph C, Sohn OS, El-Bayoumy K and Reddy BS. 1991. Mechanisms of benzyl selenocyanate inhibition of axoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 51:2826-2830. Filipe MI. 1975. Mucos secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and hictochemical study. Br J Cancer 32:60-77. Fosslien E. 2000. Molecular pathology of cyclooxygenases-2 in neoplasia. Ann Clin Lab Sci 30: 3-21. Garcia MD, Saenz MT, Gomez MA and Fernandez Ma. 1999. Topical antiinflammatory activity of phytosterosis isolated from Eryngium foetidum on chronic and acute inflammation models. Phytother Res 13(1):78-80. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P and Booker SV. 1993. Treatment of colonic and rectal adenomas with sulidac in familial adenomatous polyposis. The New Eng J of Med 328:1313-1316. Glei M, Kirmse A, Habermann N, Persin C and Pool-Zobel BL. 2006. Bread enriched with green coffee extract has chemoprotective and antigenotoxic activities in human cells. Nutr Cancer 56(2):182-192. Gomez MA, Saenz MT, Garcia MD and Fernandez MA. 1999. Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Z Naturforsch [C] 54(11):937-941. Grisham MB, Heuil DJ and Wink DA. 2000. Review article: chronic inflammation and reactive oxygen and nitrogen metabolism-implication in DNA damage and mutagnesis. Aliment Pharmacol Ther 14(S):3-9. Hamilton SR. 1989. Experimental models of colorectal carcinogenesis. In Colorectal Cancer: From Pathogenesis to Prevention, H.K. Seitz, U.A. Simanowski and N.A. Wright (Ed), p202-216, Spring-Verlag Berlin, Heidelberg, Berlin. Hao XP, Pretlow TG, Rao JS and Pretlow TP. 2001. Inducible nitric oxide synthase is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61:419-422. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley B and Neoptolemos JP. 1994. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 81:1219-1223. Hsia SM, Chiang W, Kuo YH, Wang PS. 2006. Downregulation of progesterone biosynthesis in rat granulose cells by adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf.) bran extracts. International J Impotence Research 18(3): 264-274. Hsu HY, Lin BF, Lin JY, Kuo CC, Chiang W. 2003. Suppression of allergic reactions by dehulled adlay in association with the balance of Th1/Th2 cell responses. J Agric Food Chem 51: 3763-3769. Hudson EA, Dinh PA, Kokubun T, Simmonds MSJ and Gescher A. 2000. Characterization of potentially chemoprevention phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiology, Biomarker & Prevention 9:1163-1170. Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, Yamashita I, Inoue M and Nakada H. 2003. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. PANS 100:2736-2741. Itzkowitz SH. 2002. Cancer prevention in patients with inflammatory bowel disease. Gastrolenterol Clin North 31:1133-1144. Janicke B, Onning G and Oredsson SM. 2005. Differential effects of ferulic acid and p-coumaric acid on S phase distribution and length of S phase in the human colonic cell line Caco-2. J Agric Food Chem 53(17):6658-6665. Janne PA and Mayer RJ. 2000. Chemoprevention of colorectal cancer. N Engl J Med 342:1960-1968. Jenab M, Chen JM, Thompson LU. 2001. Sialomucin production in aberrant crypt foci relates to degree of dysplasia and rate of cell proliferation. Cancer Lett 165:19-25. Jenab M and Thompson LU. 1998. The influence of phytic acid in wheat bran on early biomarkers of colon carcinogenesis. Carcinogenesis 19:1087-1092. Kargman SL, O’Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559. Kawabata K, Yamamoto T, Hara A, Shimizu M, Yamada Y, Matsunaga K, Tanaka T and Mori H. 2000. Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Lett 157(1):15-21. Kawamori T, Tanaka T, Kojima T, Suzui M, Ohnishi M and Mori H. 1994. Suppression of azoxymethane-induced rat colon aberrant crypt foci by dietary protocatechuic acid. Jpn J Cancer Res 85(7):686-691. Kawamori T, Tanaka T, Hara A, Yamahara J and Mori H. 1995. Modifying effects of naturally occurring product on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Cancer Res 55:1277-1282. Kune GA. 1996. Causes and Control of Colorectal Cancer. Kluwer Academic Publishers, Norwel, MA. Kuo C.-C., Shih, M.-C., Kuo, Y.-H., and Chiang, W. 2001. Antagonism of free-radical induced damage of adlay seed and its antiproliferative effect in human histolytic lymphoma U937 monocytic cells. J Agric Food Chem 49: 1564-1570. Kurata R, Adachi M, Yamakawa O and Yoshimoto M. 2007. Growth suppression of human cancer cells by polyphenolics from sweet potato (lpomoea batatas L.) leaves. J Agric Food Chem 55(1):185-190. Lashner BA. 1994. Colorectal cancer in ulcerative colitis patients: survival curves and surveillance. Clevel Clin J Med 61:272-275. Leathy KM, Koki AT and Masferrer JL. 2000. Role of Cyclooxygenases in angiogenesis. Curr Med Chem 7: 1163-1170. Lee JY, Jang YW, Kang HS, Moon H, Sim SS and Kim CJ. 2006. Anti-inflammatory action of phenolic compounds from Gastrodia elata roots. Arch Pharm Res 29(10):849-858. Lee MY, Lin HY, Cheng F, Chiang W and Kuo YH. 2008. Isolation and characterization of new lactam compounds that inhibit lung and colon cancer cells from adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf) bran. Food Chem Toxicol 46(6):1933-1999. Marnett LJ. 1994. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 13: 303-308. McLellan EA and Bird RP. 1988. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 48:6187-6192. Moochhala S, Chhatwal VJS, Chan STF, Ngoi SS, Chia YW and Rauff A. 1996. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 17:1171-1174. Moody GA, Jayanthi V, Probert CS, Mackay H and Maybcrry JF. 1996. Long term therapy with sulphasalaxine protects against colorectal cancer in ulcerative colotis; a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepaiol 8:1179-1183. Morishita Y, Yoshimi N, Kawabata K, Matsunaga K, Sugie S, Tanaka T and Mori H. 1997. Regressive effects of various chemopreventive agents on azoxymethane-induced aberrant crypt foci in the rat colon. Jpn J Cancer Res 88(9):815-820. Novarro A, Heras BDL and Villar A. 2001. Anti-inflammatory and immunomodulating properties of a sterol fraction from Sideritis foetens CLEM. Pharm Bull 24(5):470-473. Oshima H and Bartsch H. 1994. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Res 305:253-264. Ohta T, Takahashi M and Ochiaic A. 2005. Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett 239:246-253. Parnaud G, Tache S, Peiffer G and Corpet DE. 1999. Polyethylene-glycol suppresses colon cancer and cause dose-dependent regression of azoxymethane-induced aberrant crypt foci in rats. Cancer Res 59:5143-5147. Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE. 1994. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15:1049-1054. Pretlow TP, Barrow BJ, Ashton WS, O’Riordan MA, Pretlow TG, Jurcisek JA and Stello TA. 1991. Aberrant crypt foci: Putative preneoplastic foci in human colonic mucosa. Cancer Res 51:1564-1567. Reeves PG. 1997. Components of AIN-93 diets as improvements in the AIN-76A diet. J Nutr 127:838S-841S. Reya T and Clevers H. 2005. Wnt signaling in stem cells and cancer. Nature 434:843-850. Roncucci L, Stamp D, Medline A, Cullen JB and Bruce WR. 1991. Identification and qualification of aberrant crypt foci and adenoma in the human colon. Hum Pathol 22:287-294. Roncucci L. 1992. Early events in human colorectal carcinogenesis aberrant crypts and microadenoma. Ital Gastroenterol 24:498-501. Sancho E, Batlle E and Clevers H. 2004. Signalling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol 20:695-723. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T. 1995. Expression of Cyclooxygenases-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789. Sengupta A, Ghosh S and Das S. 2003. Tomato and garlic can modulate azoxymethane-induced colon carcinogenesis in rats. Eur J Cancer Prev 12(3):195-200. Seo WG, Pae HO, Chai KY, Yun YG, Kwon TH, Chung HT. 2000. Inhibitory effects of methanol extract of seeds of Job’s tears (Coix lachryma-jobi L. var. ma-yuen) nitric oxide and superoxide production in RAW 264.7 macrophages. Immunopharmacol Immuntoxicol 22: 545-554. Shih CK, Chiang WC and Kuo ML. 2004. Effects of adlay on azoxymethane-induced colon carcinogenesis in rats. Food Chem Toxicol 42:1339-1347. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T and Stenson WF. 1998. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297-306. Singh J, Hamid R and Reddy RS. 1997. Dietary fat and colon cancer : modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 57:3465-3470. Sohn KJ, Puchyr M, Salomon RN, Cook FG, Fung L, Choi SW, Mason JB, Medline A and Kim YI. 1999. The effect of dietary folate on APC and p53 mutations in the dimethylhydrazine rat model of colorectal cancer. Carcinogenesis 20:2345-2350. Sun HD, Lin ZW, Niu FD, Lin LZ, Chai HB, Pezzuto JM, Cordell GA. 1995. Cytotoxic ent-kaurene diterpenoids from three Isodon species. Phytochemistry 38(2): 437-442. Takahashi T and Wakabayashi K. 2004. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodens. Cancer Sci 95:475-480. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y. 1998. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339:1277-1284. Tanaka T, Nishikawa A, Shima H, Sugie S, Shinoda T, Yoshimi N, Iwata H and Mori H. 1990. Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in the rats and hamsters. Basic Life Sci 52:429-440. Tanaka T, Kojima T, Suzui M and Mori H. 1993. Chemoprevention of colon carcinogenesis by the natural product of a simple phenolic compound protocatechuic acid: suppressing effects on tumor development and biomarkers expression of colon tumorigenesis. Cancer Res 53:3908-3913. Tanaka T, Kojima T, Kawamori T and Moti H. 1995. Chemoprevention of digestive organs carcinogenesis by natural product protocatechuic acid. Cancer 75:1433-1439. Tanaka T, Makita H, Kamabata K, Mori H, Sumida T, Tanaka T and Ogawa H. 1997. Chepoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occuring flavonoids, diosmin and hesperidin. Carcinogenesis 18:957-965. Tanaka T, Shimizu M, Kohno H, Yoshitani S, Tsukio Y, Murakami A, Safitri R, Takahashi D, Tamamoto K, Ohigashi H and Mori H. 2001. Chemoprevention of azoxymethane-induced rats aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. Life Sci 69:1935-1945. Tsujii M and DuBios RN. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501. Tsuii M, Kawano S, DuBios RN. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340. Tsukamoto T, Kozaki K, Nishikawa Y, Yamamoto M, Fukami H, Inoue M, Wakabayashi K and Tatematsu M. 1999. Development and distribution of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-induced aberrant crypt foci in the rat large intestine. Jpn J Cancer Res 90:720-725. Ukita T, Tanimura A. 1961. Studies on the anti-tumor component in the seeds of Coix lachryma-jobi L. var. ma-yuen (Roman) stapf I. Isolation and anti-tumor activity of coixenolide. Chem Pharm Bull 9: 43-46. Wargovich MJ, Jimenez A, Mckee K, Steele VE, Velasco M, Woods J, Price R, Gray K and Kelloff GJ. 2000. Effect of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21:1149-1155. Yang VW, Shield JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR and Giardiello FM. 1998. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 58:1750-1753. Yoshimi N, Morioka T, Kinjo T, Inamine M, Kaneshiro T, Shimizu Y, Suzui M, Yamada Y and Mori H. 2004. Histological and immunohistochemical observations of mucin-depleted foci (MDF) stained with alcian blue, in rat colon carcinogenesis induced with 1,2-dimethylhydrazine dihydrochloride. Cancer Sci 95:792-797. Zheng Q, Hirose Y, Yoshimi N, Murakami A, Koshimizu K, Ohigashi H, Sakata K, Matsumoto Y, Sayama Y and Mori H. 2002. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in the human colon cancer cells. J Cancer Res and Clinical Oncology 128:539-546. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41024 | - |
dc.description.abstract | 惡性腫瘤位居2007年台灣十大死因之首位,其中結腸直腸癌(大腸癌)高居惡性腫瘤死因的第三位;流行病學研究顯示大腸癌與飲食因子關係密切,因此藉由飲食預防大腸癌深具發展潛力。薏苡(adlay, Coix lachryma-jobi L. var. ma-yuen Stapf)為禾本科植物,是中國傳統藥食同源之食材,具有消炎和抗腫瘤等功效。近年來大腸癌的相關研究證實,在動物飼料中部分以糙薏仁、薏仁麩皮及薏仁麩皮乙醇萃取物取代皆能有效降低大腸癌癌前病變異常腺窩病灶(aberrant crypt foci, ACF)數目;且薏仁麩皮甲醇萃取之乙酸乙酯層區分物對人類大腸癌細胞株(human colon cancer cells,HT-29)具抑制生長的作用。本研究利用動物模式探討不同劑量的薏仁麩皮乙醇萃取之乙酸乙酯層區分物(ethyl acetate fraction of adlay bran ethanolic extract, ABE-Ea)對大腸癌的預防效果,並探討此區分物是否藉由調控發炎相關因子來影響大腸癌的致癌過程。實驗組別分成管餵蒸餾水之空白組(0.5 ml water/day; blank, B)、0.5%羧甲基纖維素(carboxymethyl cellulose, CMC)之負控制組(0.5 ml 0.5% CMC/day;negative control, NC)、抗發炎藥物 piroxicam之正控制組(1.50 mg piroxicam/day;positive control, PC)、薏仁麩皮乙醇萃取之乙酸乙酯層區分物低劑量組(8.64 mg ABE-Ea /day;low level of ABE-Ea, L)、薏仁麩皮乙醇萃取之乙酸乙酯層區分物中劑量組(17.28 mg ABE-Ea /day;medium level of ABE-Ea, M)及薏仁麩皮乙醇萃取之乙酸乙酯層區分物高劑量組(34.56 mg ABE-Ea /day;high level of ABE-Ea, H),並腹腔注射1,2-dimethylhydrazin (DMH)誘發F344鼠大腸病變,DMH劑量為40 mg/kg body weight,每週注射一劑,共注射4週(空白組注射等劑量生理食鹽水),誘發9週及18週後將動物犧牲,從形態學上觀察大腸癌癌前病變ACF、大腸黏液素(mucin)及大腸腫瘤生成的前驅指標MDF (mucin-depleted foci, 缺乏黏液素病灶),並分析大腸黏膜上與發炎相關之誘導型一氧化氮合成酶(inducible nitric oxide synthase, iNOS)與第二型環氧合酶(cyclooxygenase-2, COX-2)的蛋白質表現量。實驗結果顯示,ABE-Ea顯著降低含1個異常腺窩之ACF數及抑制含7和8個異常腺窩之ACF的形成,顯示ABE-Ea能抑制ACF內腺窩的分裂;ABE-Ea些微降低遠端大腸之ACF數,並顯著抑制ACF上黏液素的轉變及抑制大腸黏膜COX-2蛋白的表現,顯示ABE-Ea可降低發炎反應而延緩大腸的癌化。實驗組中以17.28 mg/day組效果最好,結果顯示可顯著降低含1個異常腺窩之ACF數、降低單位長度之ACF數及抑制MDF的生成。本研究結果顯示ABE-Ea藉由影響不同類型的癌前病變及降低大腸的發炎反應,進而延緩大腸的癌化。 | zh_TW |
dc.description.abstract | Malignant neoplasm is the first cause of ten leading causes of death in 2007 in Taiwan and colorectal cancer is the third cause of cancer death in Taiwan. Epidemiological studies have indicated that colorectal cancer is strongly associated with diet, and thus the occurrence of colorectal cancer may be prevented by dietary modification. Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) is a grass crop used in traditional Chinese medicine and as a nutritious food. It has been reported that adlay pocesses anti-inflammatory and anti-tumor activity. In animal model, recent studies have shown that diet substituted with 20% dehulled adlay, 1.6% adlay bran and 0.29% ethanolic extract of adlay bran can significantly suppress the formation of preneoplastic lesions (aberrant crypt foci, ACF) in colon carcinogenesis. In addition, ethyl acetate fraction of adlay bran methanolic extract exhibited the growth-inhibiting effect on HT-29 human colon cancer cells. The purpose of this study was to investigate the effect of different levels of ethyl acetate fraction of adlay bran ethanolic extract (ABE-Ea) on colon carcinogenesis in animal model and to investigate whether ABE-Ea could affect colon carcinogenesis through modulation of inflammation-related proteins. Male F344 rats consumed different samples (blank: 0.5 ml water/day, negative control: 0.5% carboxymethyl cellulose /day, positive control: 1.50 mg piroxicam/day, low level of ABE-Ea: 8.64 mg ABE-Ea/day, medium level of ABE-Ea: 17.28 mg ABE-Ea/day, high level of ABE-Ea: 34.56 mg ABE-Ea/day) by tube feeding and received colon-specific carcinogen 1,2-dimethylhydrazin (DMH) by intraperitoneal injection (40 mg/kg body weight, once a week for 4 weeks, blank were received the same dosage of normal saline). After 9 and 18 weeks of induction, rats were sacrificed and colons were removed to examine for ACF, mucin and mucin-depleted foci (MDF, preneoplastic lesions of colon cancer). Colonic mucosa was examined for inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression. The results indicated that ABE-Ea significantly reduced the numbers of ACF with 1 crypt and inhibited the formation of ACF with 7 and 8 crypts, showing that ABE-Ea could suppress the fission of ACF. ABE-Ea slightly reduced the numbers of ACF in distal colons, significantly suppressed the mucin alteration of ACF and significantly suppressed the COX-2 expression in overall colons, showing that ABE-Ea could delay the colon carcinogenesis by suppressing colonic inflammation. ABE-Ea at the level of 17.28 mg/day exhibited the best preventive effects on colon carcinogenesis as it significantly reduced the number of ACF with 1 crypt, reduced the number of ACF/cm and inhibited the formation of MDF. Results from this study suggest that ABE-Ea reduces different preneoplastic lesions, reduces colonic imflammation and thus delays colon carcinogenesis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T17:12:28Z (GMT). No. of bitstreams: 1 ntu-97-R95641011-1.pdf: 12196245 bytes, checksum: c97d31e76e4ef42ccd377819949f0f0e (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 中文摘要........................................................................................................ Ⅰ
英文摘要........................................................................................................ Ⅲ 英文縮寫對照表............................................................................................ Ⅴ 目錄................................................................................................................ Ⅶ 表目錄............................................................................................................ Ⅹ 圖目錄............................................................................................................ ⅩⅠ 第一章 前言.................................................................................................. 1 第二章 文獻回顧.......................................................................................... 2 2.1 大腸癌................................................................................................. 2 2.1.1 大腸的解剖及腸壁構造.............................................................. 2 2.1.2 大腸癌的形成.............................................................................. 4 2.1.3 大腸癌的分期.............................................................................. 6 2.1.4 大腸癌與ACF.............................................................................. 9 2.1.5 大腸癌與黏液素.......................................................................... 11 2.1.6 大腸癌與發炎.............................................................................. 14 2.1.7 大腸癌與iNOS............................................................................. 15 2.1.8 大腸癌與COX-2.......................................................................... 16 2.1.9 DMH的致癌機制......................................................................... 16 2.2 薏苡..................................................................................................... 19 2.2.1 薏苡簡介...................................................................................... 19 2.2.2 薏苡之機能性研究...................................................................... 19 2.2.3 薏苡之大腸癌研究...................................................................... 22 第三章 研究目的.......................................................................................... 24 第四章 材料與方法...................................................................................... 25 4.1 實驗材料............................................................................................. 25 4.1.1 實驗動物...................................................................................... 25 4.1.2 飼料組成...................................................................................... 25 4.1.3 實驗藥品...................................................................................... 25 4.1.4 儀器設備...................................................................................... 27 4.2 實驗方法............................................................................................. 28 4.2.1 薏仁麩皮來源.............................................................................. 28 4.2.2 實驗樣品萃取流程…….............................................................. 28 4.2.3 動物分組與飼養.......................................................................... 30 4.2.4 實驗架構及流程.......................................................................... 31 4.3 分析項目............................................................................................. 33 4.3.1 實驗飼料配方.............................................................................. 33 4.3.2 大腸組織...................................................................................... 33 4.3.2.1 ACF分析................................................................................ 33 4.3.2.2 黏液素分析........................................................................... 34 4.3.2.3 黏膜iNOS蛋白質分析......................................................... 34 4.3.2.4 黏膜COX-2蛋白質分析...................................................... 35 4.4 統計分析……………………………………………………………. 37 第五章 結果.................................................................................................. 38 5.1 F344鼠攝食及生長狀況...................................................................... 38 5.2 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸ACF數 目及生長特質之影響........................................................................ 40 5.3 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸ACF分 布之影響............................................................................................ 46 5.4 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠遠端大腸黏液 素之影響............................................................................................ 48 5.5 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸癌前期病 變MDF之影響................................................................................... 52 5.6 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸iNOS蛋 白表現量之影響................................................................................ 56 5.7 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸COX-2 蛋白表現量之影響............................................................................ 59 第六章 討論.................................................................................................. 63 6.1 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸ACF之 影響.................................................................................................... 63 6.2 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠遠端大腸黏液 素之影響............................................................................................ 65 6.3 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸MDF之 影響.................................................................................................... 66 6.4 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對F344鼠大腸發炎反應 相關指標之影響................................................................................ 68 第七章 結論.................................................................................................. 74 參考文獻........................................................................................................ 75 附錄1薏仁麩皮甲醇萃取之乙酸乙酯層區分物所分離出純化合物對 HT-29之抑癌及抗發炎活性……………………………………... 88 附錄2薏仁麩皮甲醇萃取之乙酸乙酯層區分物所分離出純化合物之化 學結構…………………………………………………………….. 89 附錄3 期刊論文初稿……….……………………………………………... 93 | |
dc.language.iso | zh-TW | |
dc.title | 薏仁麩皮乙醇萃取之乙酸乙酯層區分物對DMH誘發F344鼠大腸癌前期病變之預防效果 | zh_TW |
dc.title | Preventive effects of ethyl acetate fraction of adlay bran ethanolic extract on DMH-induced preneoplastic lesions of colon in F344 rats | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 施純光 | |
dc.contributor.oralexamcommittee | 郭明良,沈立言,江孟燦 | |
dc.subject.keyword | 薏仁麩皮,大腸癌,異常腺窩病灶,黏液素,黏液素缺乏病灶,誘導型一氧化氮合成酶,第二型環氧合酶, | zh_TW |
dc.subject.keyword | adlay bran,colon cancer,aberrant crypt foci (ACF),mucin,mucin-depleted foci (MDF),inducible nitric oxide synthase (iNOS),cyclooxygenase-2 (COX-2), | en |
dc.relation.page | 86 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-28 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 11.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。